Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1039-1049

  Owen, Joel S ^a,d   Melhem, Murad ^a,e   Passarell, Julie A ^a   D'Andrea, Denise ^b   Darwish, Mona ^b   Kahl, Bradley ^c  

^a Albany Medical College   (United States)

^b CEPHALON INC   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNION UNIVERSITY   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Bendamustine; Exposure response; Metabolite; Nausea; Pharmacokinetics

Indexed keywords

ANTIEMETIC AGENT; BENDAMUSTINE; DRUG METABOLITE; RITUXIMAB; SEROTONIN ANTAGONIST;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149406113     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1254-8     Document Type: Article

References (26)

1. LM Leoni B Bailey J Reifert, et al. 2008 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other Alkylating agents Clin Cancer Res 14 309 317 1:CAS:528:DC%2BD1cXoslKk 10.1158/1078-0432.CCR-07-1061 18172283 (Pubitemid 351378007)
2. D Strumberg A Harstrick K Doll, et al. 1996 Bendamustine hydrochloride activity against doxorubicin-resistent human breast carcinoma cell lines Anticancer Drugs 7 415 421 1:CAS:528:DyaK28XkslWru7g%3D 10.1097/00001813- 199606000-00007 8826610 (Pubitemid 26249195)
3. JW Friedberg P Cohen L Chen KS Robinson A Forero-Torres AS La Casce, et al. 2008 Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 204 210 1:CAS:528:DC%2BD1cXitVWit70%3D 10.1200/JCO.2007.12.5070 18182663
4. MA Bergmann 2006 Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CL Study Group Haematologica 90 1357 1364
5. W Ponisch PS Mitrou K Merkle M Herold M Assmann G Wilhelm, et al. 2006 Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German study group of hematology and oncology (OSHO) J Cancer Res Clin Oncol 132 205 212 1:STN:280:DC%2BD28%2Fktlaqsw%3D%3D 10.1007/s00432-005-0074-4 16402269 (Pubitemid 43144255)
6. G von Minckwitz I Chernozemsky L Sirakova P Chilingirov R Souchon N Marschner, et al. 2005 Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC Anticancer Drugs 16 871 877 10.1097/01.cad.0000175587.31940.19 (Pubitemid 41215753)
7. A Schmittel M Knodler P Hortig K Schulze E Thiel U Keilholz 2007 Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients Lung Cancer 55 109 113 10.1016/j.lungcan.2006.09.029 17097191 (Pubitemid 46043579)
8. J Teichert F Baumann Q Chao C Franklin B Bailey L Hennig, et al. 2007 Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride Cancer Chemother Pharmacol 59 759 770 1:CAS:528:DC%2BD2sXjt1Wmt7g%3D 10.1007/s00280-006-0331-5 16957931 (Pubitemid 46440598)
9. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al (2009) Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study. Cancer Nov 4 (Epub ahead of print)
10. World Health Organization (1998) Executive summary from the world symposium on primary pulmonary hypertension. World Health Organization, Evian, France
11. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1:STN:280:DyaE28%2FnsF2isw%3D%3D 10.1159/000180580 1244564
12. National Cancer Institute. Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events v3.0 (CTCAE). http://www.ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed 01 Aug 2007
13. C Schwänen T Hecker G Hubinger M Wolfle W Rittgen L Bergmann, et al. 2002 In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia Leukemia 16 2096 2105 10.1038/sj.leu.2402651 12357363 (Pubitemid 35203454)
14. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors, et al. 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D 10561185
15. Beal SL, Sheiner LB, Boeckmann AJ (1989-2006) NONMEM users guides. Ellicott City, Maryland
16. RD Mosteller 1987 Simplified calculation of body-surface area N Engl J Med 317 1098 1:STN:280:DyaL1c%2FhsVSmtw%3D%3D 3657876
17. Peck CC, Conner DP, Murphy MG (1989) Bedside clinical pharmacokinetics: simple techniques for individualizing drug therapy. Vancouver, Washington
18. LB Sheiner SL Beal 1981 Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 503 512 1:STN:280:DyaL38%2FnslGruw%3D%3D 10.1007/BF01060893 7310648
19. H Patel MJ Egorin SC Remick D Mulkerin CHM Takimoto JH Doroshow, et al. 2004 Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing J Clin Oncol 22 14S suppl 6051
20. Food and Drug Administration (1998) Guidance for industry pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Docket #97D-0214
21. M Rasschaert D Schrijvers BJ Van den J Dyck J Bosmans K Merkle, et al. 2007 A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumours Br J Cancer 96 1692 1698 1:CAS:528:DC%2BD2sXlvVShsbg%3D 10.1038/sj.bjc.6603776 17486132 (Pubitemid 46847200)
22. M Rasschaert D Schrijvers J Dyck J Bosmans K Merkle, et al. 2007 A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors Anticancer Drugs 18 587 595 1:CAS:528: DC%2BD2sXjvVKiu7c%3D 10.1097/CAD.0b013e3280149eb1 17414628 (Pubitemid 46597413)
23. Cephalon Inc (2009) Treanda (bendamustine) for injection. Cephalon Inc, Fraser PA (product information)
24. National Cancer Institute (2007) Fatigue (PDQ) health professional version. National Cancer Institute, Bethesda
25. PJ Hesketh 1999 Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice Oncologist 4 191 196 1:STN:280:DyaK1Mzit1yqsw%3D%3D 10394587
26. National Cancer Institute (2007) Nausea and vomiting (PDQ) health profession version. National Cancer Institute, Bethesda